ANDA 203704, held by Qilu Antibiotics. Cefepime Hydrochloride.
As of Nov 16, 2026, ANDA 203704 (Cefepime Hydrochloride), held by Qilu Antibiotics, was first approved by FDA on Feb 1, 2016, with 4 approved supplements and 0 published complete response letters.
Cefepime for Injection is a cephalosporin antibacterial indicated for the treatment of the following infections caused by susceptible strains of the designated microorganisms:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 1, 2016 | Original application | Approved | None posted |
| Cefepime HydrochlorideEQ 500MG BASE/VIAL · injectable;injection | Cefepime Hydrochloride | Rx |
| Cefepime HydrochlorideEQ 1GM BASE/VIAL · injectable;injection | Cefepime Hydrochloride | Rx |
| Cefepime HydrochlorideEQ 2GM BASE/VIAL · injectable;injection | Cefepime Hydrochloride | Rx |
| Jan 28, 2022 | Supplement 14Labeling · Standard review | Approved | None posted |
| Feb 11, 2020 | Supplement 7Labeling · Standard review | Approved | None posted |
| Aug 15, 2017 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 15, 2017 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 1, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters